Break into a new market or add new products to your current portfolio with these licensing opportunities. Partner with 3M Drug Delivery Systems on innovations that are ready to license today.
As science continues to elucidate the complex controls governing immune responsiveness, we can expect to see an increasing role for TLR agonists. With a variety of molecules at various stages of development, 3M is your go-to partner to expand your portfolio with licensing opportunities in this new and exciting arena.
3M offers a portfolio of license-ready toll-like receptor (TLR) agonists at various stages of development. Unlike most other TLR agonists, our molecules are small, easy to manufacture, stable and can be delivered by multiple routes of administration. These molecules could be used as single agents for cancer, for dermatology and asthma allergy treatment, or in combination with vaccines.
3M produced the very first TLR7 agonist product, Aldara (imiquimod 5% cream). Aldara was approved in 1997 for the topical treatment of external genital warts, actinic keratosis, and basal cell carcinoma. Since then, 3M has synthesized well over 10,000 distinct molecules that act either as selective TLR7, selective TLR8, or as TLR7/8 agonists. These agonists have potential utility against a broad spectrum of diseases, including a variety of dermatologic indications. Potential benefits of second generation topical compounds:
Current treatments for head and neck cancer are effective only for 40-50% of recipients. They have major side-effects (pain from feeding tubes, difficulty swallowing, rash, cardiac arrest), and 60% of patients are still dying.
TLR agonist 3M-052 changes everything. It’s not just a treatment. This next- generation immunotherapy could lead to a cure with far fewer side effects than standard surgical and radiation treatments.
3M-052 is the next generation of TLR 7/8 agonists for vaccine adjuvant use. Novel chemistry results in prolonged retention of adjuvants with antigen at administration site, resulting in increased cell-mediated immunity and decreased systemic cytokine production associated with adverse effects.
Bottom line: 3M-052 is less toxic and more effective.
854 is a TLR 7/8 agonist that has been formulated in an aqueous pump system for treatment of allergic rhinitis. Allergic rhinitis is considered to be a Th2-mediated disease process, and 854A has been shown to inhibit many aspects of the Th2 immune response.
TLR 7/8 agonists, like 854A, are known to:
Topical delivery to the nose inhibits various aspects of allergic rhinitis without high levels of systemic drug exposure.
Our product stimulates the body’s own immune system to kill the tumor and inhibit recurrence. Initially indicated for patients who can’t receive surgery, we believe 3M-052 will eventually replace surgery as the standard of care.
3M has a variety of molecules to be licensed for a broad range of vaccine adjuvants and non-vaccine therapeutics. For details and to discuss your TLR agonist licensing opportunities, talk to your local 3M representative, or contact us online for more information.
From development to manufacturing to licensing opportunities, find out how you can partner with 3M to help ensure your success. We offer a cost-free, no-obligation feasibility study for the first stage of assessment. Contact us to get started.